|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia.
|
31292220 |
2019 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
PCSK9 regulates LDL receptor degradation and plays key roles in hypercholesterolemia and related cardiovascular diseases.
|
31593224 |
2019 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
NMR-based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI-Study).
|
30663261 |
2019 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer.
|
29650402 |
2019 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
The discovery of PCSK9 has provided a new target for the management of hypercholesterolemia and cardiovascular risk reduction.
|
30950043 |
2019 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
In more than 80% of those with a clinical diagnosis of FH but with no detectable mutation in LDLR/APOB/PCSK9, the polygenic explanation is the most likely for their hypercholesterolaemia.
|
30270085 |
2018 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
We developed mice lacking lipin-1 in myeloid-derived cells and used adeno-associated viral vector 8 expressing the gain-of-function mutation of mouse proprotein convertase subtilisin/kexin type 9 (adeno-associated viral vector 8-proprotein convertase subtilisin/kexin type 9) to induce hypercholesterolemia and plaque formation.
|
29217509 |
2018 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Currently, statins, Ezetimibe, Bile acid sequestrants and PCSK9 inhibitors are the main therapeutic agents for the treatment of hypercholesterolemia.
|
29578362 |
2018 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Pharmacological intervention using statins and PCSK9 inhibitors have become first-line therapy in the prevention of hypercholesterolemia and atherosclerosis.
|
30115989 |
2018 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
A promising approach to treat hypercholesterolemia is inactivating the secreted protein PCSK9, an antagonist of the LDL receptor.
|
29985478 |
2018 |
|
Hypercholesterolemia
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of circulating LDL-C levels, have received considerable attention as promising non-statin therapeutic options for the management of hypercholesterolemia.
|
29411675 |
2018 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel therapy to treat hypercholesterolaemia and related cardiovascular diseases.
|
29800228 |
2018 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Increasing the dose of AAV8-PCSK9 threefold in female mice rescued the hypercholesterolemia phenotype but did not result in full restoration of AAV8-PCSK9 transduction of livers in female mice compared to the low-dose male mice.
|
30253291 |
2018 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
The Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia.
|
29667842 |
2018 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
The results suggested that this strategy could be applied for evaluating potential bioactive compounds inhibiting the interaction of PCSK9/LDLR and this strategy could accelerate the discovery of new drug candidates for the treatment of PCSK9-mediated hypercholesterolemia.
|
30235833 |
2018 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9) is a novel strategy to treat hypercholesterolemia and reduce cardiovascular events.
|
29748315 |
2018 |
|
Hypercholesterolemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PheWAS revealed a significantly reduced risk of hypercholesterolemia (odds ratio [OR] 0.68, p = 7.6 × 10<sup>-4</sup>) in association with a known loss-of-function variant in PCSK9, R46L.
|
29185237 |
2018 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia.
|
29649884 |
2018 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Compared with wild type, PCSK9-GOF pigs had elevated cholesterol, triglyceride, and blood pressure levels at 3 and 6 months.
|
29175268 |
2018 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this review, we will summarize the most recent findings of basic and clinical studies which focus on PCSK9 function, regulation and therapeutic target for the treatment of hypercholesterolemia and associated cardiovascular diseases.
|
29210646 |
2018 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor is a new treatment option for patients with hypercholesterolemia.
|
29148854 |
2018 |
|
Hypercholesterolemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Additionally, in the entire study group (n=401), PCSK9 R496W and D374Y mutation carriers had increased total cholesterol (p=0.021), triglycerides (p=0.0001), HDL cholesterol (p=0.028), and low-density lipoproteins (LDL) cholesterol (p=0.028) levels.
|
29724976 |
2018 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Circulating PCSK9 causes hypercholesterolemia by reducing LDL receptors in hepatocytes.
|
29451410 |
2018 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
To assess the lipid-lowering efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in people with hypercholesterolaemia and prediabetes at baseline vs people with normoglycaemia at baseline in a pooled analysis of 10 ODYSSEY phase III trials.
|
28799203 |
2018 |
|
Hypercholesterolemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Given that new onset diabetes mellitus (NODM) and worsening of glucose control in patients with established type 2 diabetes mellitus (T2DM) is related to low density lipoprotein cholesterol (LDL-C) reduction, it would be of great interest to investigate if this is also the case for proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, which have recently be licensed for the treatment of hypercholesterolaemia.
|
28128061 |
2017 |